Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines

Cancer

Volumn 113, Issue 4, 2008, Pages 690-700

  Kidd, Mark ^a   Drozdov, Ignat ^a   Joseph, Richard ^a   Pfragner, Roswitha ^b   Culler, Michael ^c   Modlin, Irv ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c ISPEN   (United States)

Author keywords

Antiproliferative agents; Lanreotide; Neuroendocrine tumors; Octreotide; Somatostatin

Indexed keywords

ANGIOPEPTIN; BIM 23023; BIM 23120; BIM 23206; BIM 23244; BIM 23926; BIM 23A719; BIM 23A758; BIM 23A760; BIM 23A761; BIM 23A779; BIM 53061; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOPAMINE RECEPTOR STIMULATING AGENT; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG SPECIFICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG TUMOR; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMALL INTESTINE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BRONCHIAL NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOPAMINE AGONISTS; DRUG COMBINATIONS; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PEPTIDES, CYCLIC; SIGNAL TRANSDUCTION; SOMATOSTATIN;

EID: 50249160709     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23700     Document Type: Article

References (39)

1. Modlin I, Lye K, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959.
2. Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol. 2008;20:1-12.
3. Gustafsson BI, Kidd M, Chan AK, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer. 2008 (in press).
4. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist. 2005;10:123-131.
5. Modlin IM, Oberg K, Chung DC, et al. The current status of gastroenteropancreatic neuroendocrine tumors. Lancet Oncol. 2008;9:61-72.
6. Kosmidis PA. Treatment of carcinoid of the lung. Curr Opin Oncol. 2004;16:146-149.
7. Modlin IM, Latich I, Kidd M, Zikusoka M, Eick G. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol. 2006;4:526-547.
8. van der Hiel B, Stokkel MP, Chiti A, et al. Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide. Eur J Endocrinol. 2003;149:479-483.
9. Lin JD, Lee ST, Weng HF. An open, phase III study of lanreotide (Somatuline PR) in the treatment of acromegaly. Endocr J. 1999;46:193-198.
10. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008;13:822-840.
11. Gruszka A, Ren SG, Dong J, Culler MD, Melmed S. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology. 2007;148:6107-6114.
12. Ren SG, Kim S, Taylor J, et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab. 2003;88:5414-5421.
13. Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed toward multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol. 2005;153:135-141.
14. Phelps RM, Johnson BE, Ihde DC, et al. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl. 1996;24:32-91.
15. Pfragner R, Wirnsberger G, Niederle B, et al. Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I): characterization and effects of 5-azacytidine on proliferation. Int J Oncol. 1996;8:513-520.
16. Kidd M, Eick G, Modlin I, Pfragner R, Champaneria M, Murren J. Further delineation of the continuous human neoplastic enterochromaffin (EC) cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. J Mol Endocrinol. 2007;38:181-192.
17. Kidd M, Schally AV, Pfragner R, Malfertheiner MV, Modlin IM. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. Cancer. 2008;112:1404-1414.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
19. Kidd M, Modlin I, Eick G, Camp R, Mane S. Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. Am J Physiol. 2007;292:G191-G200.
20. Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer. 2005;103:229-236.
21. Kidd M, Nadler B, Mane SM, et al. GeneChip, geNorm and gastrointestinal tumors: novel reference genes for real-time PCR. Physiol Genom. 2007;30:363-370.
22. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.
23. Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest. 2006;29:826-830.
24. Cervia D, Zizzari P, Pavan B, et al. Biological activity of somatostatin receptors in GC rat tumour somatotrophs: evidence with sst1-sst5 receptor-selective nonpeptidyl agonists. Neuropharmacology. 2003;44:672-685.
25. Ono K, Suzuki T, Miki Y, et al. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Res. 2007;27:2231-2239.
26. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008;15:257-266.
27. Conti M. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol Endocrinol. 2000;14:1317-1327.
28. Vossler MR, Yao H, York RD, Pan MG, Rim CS, Stork PJ. cAMP activates MAP kinase and Elk-1 through a B-Raf-and Rap1-dependent pathway. Cell. 1997;89:73-82.
29. Pages P, Benali N, Saint-Laurent N, et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem. 1999;274:15186-15193.
30. Guillermet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C. Physiology of somatostatin receptors. J Endocrinol Invest. 2005;28(11 suppl):5-9.
31. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002;1:639-649.
32. Lee YJ, Shukla SD. Pro- and anti-apoptotic roles of c-Jun N-terminal kinase (JNK) in ethanol and acetaldehyde exposed rat hepatocytes. Eur J Pharmacol. 2005;508:31-45.
33. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP kinases. Nature. 1991;353:670-674.
34. Oberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy. 2001;47(suppl 2):40-53.
35. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157-198.
36. Kidd M, Modlin IM, Pfragner R, et al. Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-betal-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1. Cancer. 2007;109:2420-2431.
37. Kidd M, Modlin I, Shapiro M, et al. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol. 2007;13:5208-5216.
38. O'Toole D, Saveanu A, Couvelard A, et al. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol. 2006;155:849-857.
39. Ferone D, Saveanu A, Culler MD, et al. Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol. 2007;156(suppl 1):S23-S28.